Menu

Press Releases

Date Summary View
Toggle Summary (Hebrew) RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients) View HTML
Toggle Summary RedHill Biopharma engages with CRO for potential pivotal trial with RHB-102 (prevention of nausea & vomiting in cancer patients) View HTML
Toggle Summary (Hebrew) RedHill Biopharma appoints Prof. Colm O'Morain, MD as Lead Investigator for the European Phase III trial with RHB-104 (Crohn's) View HTML
Toggle Summary RedHill Biopharma appoints Prof. Colm O'Morain, MD as Lead Investigator for the European Phase III trial with RHB-104 (Crohn's) View HTML
Toggle Summary RedHill Biopharma appoints Prof. David Y. Graham, MD as Lead Investigator for the US pivotal trial with RHB-104 (Crohn's) View HTML
Toggle Summary (Hebrew) RedHill Biopharma appoints Prof. David Y. Graham, MD as Lead Investigator for the US pivotal trial with RHB-104 (Crohn's) View HTML
Toggle Summary RedHill Biopharma Acquires Exclusive Rights to a MAP Bacterium Companion Diagnostic Test for its RHB-104 (Crohn's) View HTML
Toggle Summary IntelGenx and RedHill Sign a Binding Term-Sheet for an Anti-Psychotic Film Product View HTML
Toggle Summary (Hebrew) RedHill Biopharma Appoints Advisory Board Headed by Dr. Jeff Leighton View HTML
Toggle Summary RedHill Biopharma Appoints Advisory Board Headed by Dr. Jeff Leighton View HTML